Definium Therapeutics, Inc. Common Shares DFTX
i
Market datapartial · fetched 2026-11-12T00:55:12.814Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-20
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-11T23:41:00.940703231Z
FundamentalsAlpha Vantage · unavailable
Definium Therapeutics, Inc. Common Shares options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | 39.64 | 99.4% | 17.0% | |||
| 25Δ | 31.49 | 94.8% | 10.9% | |||
| 30Δ | 37.44 | 89.8% | 11.4% | 32.15 | 98.5% | 9.8% |
| 35Δ | 36.87 | 94.1% | 10.4% | 32.78 | 104.6% | 9.0% |
| 40Δ | 36.10 | 91.5% | 8.7% | 33.48 | 105.7% | 8.0% |
| 45Δ | 35.42 | 89.5% | 7.3% | 34.16 | 101.4% | 6.7% |
| 50Δ | 34.77 | 91.5% | 6.4% | 34.75 | 89.6% | 5.1% |
| 55Δ | 34.17 | 100.2% | 6.0% | 35.38 | 86.4% | 4.2% |
| 60Δ | 36.04 | 89.3% | 3.6% | |||
| 65Δ | 36.51 | 83.5% | 2.8% | |||
| 70Δ | 31.81 | 117.4% | 4.0% | 36.99 | 77.6% | 2.1% |
| 75Δ | 31.07 | 112.0% | 3.0% | 38.00 | 82.4% | 1.7% |
| 80Δ | 30.13 | 112.9% | 2.2% | 39.02 | 87.3% | 1.3% |
20Δ
- Pseudo strike
- 39.64
- IV
- 99.4%
- B/E move
- 17.0%
- Pseudo strike
- IV
- B/E move
25Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 31.49
- IV
- 94.8%
- B/E move
- 10.9%
30Δ
- Pseudo strike
- 37.44
- IV
- 89.8%
- B/E move
- 11.4%
- Pseudo strike
- 32.15
- IV
- 98.5%
- B/E move
- 9.8%
35Δ
- Pseudo strike
- 36.87
- IV
- 94.1%
- B/E move
- 10.4%
- Pseudo strike
- 32.78
- IV
- 104.6%
- B/E move
- 9.0%
40Δ
- Pseudo strike
- 36.10
- IV
- 91.5%
- B/E move
- 8.7%
- Pseudo strike
- 33.48
- IV
- 105.7%
- B/E move
- 8.0%
45Δ
- Pseudo strike
- 35.42
- IV
- 89.5%
- B/E move
- 7.3%
- Pseudo strike
- 34.16
- IV
- 101.4%
- B/E move
- 6.7%
50Δ
- Pseudo strike
- 34.77
- IV
- 91.5%
- B/E move
- 6.4%
- Pseudo strike
- 34.75
- IV
- 89.6%
- B/E move
- 5.1%
55Δ
- Pseudo strike
- 34.17
- IV
- 100.2%
- B/E move
- 6.0%
- Pseudo strike
- 35.38
- IV
- 86.4%
- B/E move
- 4.2%
60Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 36.04
- IV
- 89.3%
- B/E move
- 3.6%
65Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 36.51
- IV
- 83.5%
- B/E move
- 2.8%
70Δ
- Pseudo strike
- 31.81
- IV
- 117.4%
- B/E move
- 4.0%
- Pseudo strike
- 36.99
- IV
- 77.6%
- B/E move
- 2.1%
75Δ
- Pseudo strike
- 31.07
- IV
- 112.0%
- B/E move
- 3.0%
- Pseudo strike
- 38.00
- IV
- 82.4%
- B/E move
- 1.7%
80Δ
- Pseudo strike
- 30.13
- IV
- 112.9%
- B/E move
- 2.2%
- Pseudo strike
- 39.02
- IV
- 87.3%
- B/E move
- 1.3%
Options history
Table
| Date | IV (%) |
|---|---|
| 65.16% | |
| 64.28% | |
| 64.82% | |
| 63.27% | |
| 67.41% | |
| 65.18% | |
| 66.80% | |
| 67.22% | |
| 65.47% | |
| 69.49% |
Biotechnology
DMAC
DiaMedica Therapeutics Inc., a clinical-stage biopharmaceutical company, develops treatments for neurological and kidney diseases. The company is headquartered in Minneapolis,…
More →DNA
Ginkgo Bioworks Holdings (DNA) is a pioneering force in synthetic biology, leveraging advanced genetic engineering to create customized bioengineered organisms suitable for a wide…
More →DNLI
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. The company is…
More →DNTH
Dianthus Therapeutics, Inc. is a clinical-stage biotechnology company that designs, develops, and delivers novel monoclonal antibodies for people living with severe autoimmune and…
More →DRTS
Alpha Tau Medical Ltd., a clinical-stage oncology therapies company, is engaged in the research, development, and commercialization of alpha-emitting radiation therapy (Alpha…
More →DRUG
Description unavailable
More →